Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Difficulty recruiting subjects

Conditions

Asthma

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

NYU Langone Health